MPNs

The Oncologic Drug Advisory Committee of the FDA found that imetelstat has robust data supporting its use for transfusion-dependent anemia in patients with myelodysplastic syndromes.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, provided an update on developments, unmet needs, and future directions for the treatment of patients with myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.

Ropeginterferon alfa is now a recommended first-line treatment for patients with polycythemia vera, according to the National Comprehensive Cancer Network’s updated guidelines.

During a Targeted Oncology™ Case-Based Roundtable™ event, Andrew Kuykendall, MD, reviewed adverse events and dosing issues related to the 4 approved JAK inhibitors in patients with myelofibrosis.

In an interview with Targeted Oncology, Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in myeloproliferative neoplasms.

During a Targeted Oncology™ Case-Based Roundtable™ event, Raajit K. Rampal, MD, gave an overview of the classification, risk assessment, and current therapy options for patients with myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed JAK inhibitor options and the data from the PERSIST-2 trial of pacritinib. This is the first of 2 articles based on this event.

Magrolimab will no longer be in development as a treatment option for patients with hematologic malignancies.

Tamoxifen, a selective estrogen receptor modulator, shows potential as a line of treatment in some patients with myeloproliferative neoplasms.

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.

Haifa Kathrin Al-Ali, MD, discussed findings from the phase 1/2 CA011-023 study of BMS-986158 combined with ruxolitinib or fedratinib in myelofibrosis.

Findings from the MOMENTUM study evaluating momelotinib demonstrated symptom, spleen, and anemia benefits in myelofibrosis compared with danazol in previously treated patients with anemia and intermediate- or high-risk myelofibrosis.

Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.

In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed issues related to dosing and management of patients receiving ruxolitinib for myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor-naive myelofibrosis.

The use of the experimental navitoclax in combination with ruxolitinib produced impactful results for patients with myelofibrosis.

In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.

Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen T. Oh, MD, PhD, discussed with participants when they would use pacritinib for patients with thrombocytopenia related to myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.

Along with improvements shown for the primary and secondary end points of the phase 3 MANIFEST-2 trial in JAK inhibitor-naive patients with myelofibrosis, pelabresib plus ruxolitinib did not display any new safety signals.

At a live virtual event, Jeanne Palmer, MD, provided commentary on the development of myeloproliferative neoplasms in patients, particularly those with newly diagnosed aggressive myelofibrosis.

In an interview with Targeted Oncology, Joseph M. Scandura, MD, PhD, discussed research on pelabresib for the treatment of patients with myeloproliferative neoplasms.

Findings from a 5-patient study evaluating azacitidine, venetoclax, and ruxolitinib for the treatment of myeloproliferative neoplasms shows promise. More research is warranted.

During a Targeted Oncology™ Case-Based Roundtable™ event, Abdulraheem Yacoub, MD, and participants discussed the process of initiating JAK inhibitor therapy for a patient with primary myelofibrosis.

In a phase 1b trial, AVID200 demonstrated limited toxicity and improved symptom benefit when administered at 3 doses levels.

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, discussed the development of Janus kinase inhibitors and how newer therapies meet needs of patients with cytopenic myelofibrosis.